China Pharmaceutical Raw Materials: Key Strength Areas, Supply Chain Capabilities, and Global Market Position
Over the past two decades, China pharmaceutical raw materials has evolved into a foundational pillar…
News
Gumokimab Approved for Plaque Psoriasis in China: The IL-17A Therapy Landscape Continues to Evolve
On June 11, Akeso announced that its self-developed IL-17A monoclonal antibody, Gumokimab (AK111, brand name…
10 Common Questions Cancer Patients Ask: From Survival Rates to Treatment Options
Cancer treatment is often a long and uncertain journey. Global pharmaceutical distributor DengYueMed has organized…
Mazdutide vs Semaglutide: ADA 2026 DREAMS-3 Trial Shows Superior Efficacy in Type 2 Diabetes With Obesity
On June 8, Innovent Biologics announced the results of the Phase III DREAMS-3 head-to-head trial…
New Hemophilia Drug Approved in China: Bemiltenase Alfa Becomes World’s First Factor X Activator
On June 4, 2026, the NMPA officially announced that injectable Bemiltenase alfa (STSP-0601), a Class…
Access Pathways for Innovative Medicines in China: Hospitals, Pharmacies, and Pharmaceutical Distribution Channels
More and more overseas patients are beginning to explore China’s innovative drug resources in search…
May 2026 China Innovative Drug Approvals: 5 Major New Drugs Approved
China’s innovative drug industry continues to achieve major breakthroughs. According to public information released by…
Which Cancers Does China Have Advantages In? Top 5 Areas of Strength Explained
From precision medicine to immunotherapy, from novel targeted drugs to cell therapy, China has formed…
Causes of the Global Counterfeit Drug Problem and Safe Pharmaceutical Procurement Guide
In today’s increasingly complex pharmaceutical distribution system and highly active cross-border trade environment, counterfeit medicines…
China Peptide API Company Landscape and Capacity Distribution
As Semaglutide, Tirzepatide, and next-generation multi-target peptides like Retatrutide advance in development and commercialization, China’s…